Why Mounjaro Works Differently When Wegovy Plateaus
Understanding Why Wegovy May Stop Working Effectively
When Wegovy stopped working, the most common reason is weight loss plateau, which affects up to 70% of patients after 6-12 months of treatment. Wegovy works by targeting GLP-1 receptors to reduce appetite and slow gastric emptying, but your body can develop tolerance or adaptation over time. This doesn't mean treatment failure—it's a natural physiological response where the single-hormone approach reaches its maximum effectiveness. Mounjaro offers a different mechanism through dual GIP and GLP-1 receptor activation, potentially providing renewed weight loss momentum when Wegovy has stopped delivering results.
The key difference lies in Mounjaro's tirzepatide formula, which activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 pathways simultaneously. Where Wegovy's semaglutide targets only GLP-1 receptors, Mounjaro's dual action can help overcome the metabolic adaptation that causes Wegovy stopped working scenarios. Many patients who experience plateaus with single-hormone treatments find renewed progress with this dual-receptor approach, making it an excellent alternative when your current medication has reached its effectiveness ceiling.
Wegovy vs Mounjaro: Pricing and Value Comparison
Both medications are available through EverydayMeds with transparent pricing and discount codes applied at checkout. Wegovy costs £79.99 for the 0.25mg starter dose rising to £209.99 for the 2.4mg maintenance dose, while Mounjaro pricing follows a similar structure across its six dose levels (2.5mg to 15mg). New customers use code FIRST40 at checkout, whilst returning customers apply DOSE25 to reach these final prices—no additional discounts needed. Our bundle options provide convenience for longer treatment periods, such as the Intro Trio (0.25mg, 0.5mg & 1mg) for £299.99.
The value comparison becomes clearer when considering that Mounjaro offers higher maximum dosing (15mg vs Wegovy's 2.4mg equivalent), potentially providing better results for patients where Wegovy stopped working due to insufficient dose ceiling. Storage advantages also differ: Wegovy maintains stability for 6 weeks at room temperature compared to Mounjaro's 21 days, making it more travel-friendly. However, when effectiveness plateaus become the primary concern, the dual-action mechanism of Mounjaro often justifies the investment for patients seeking renewed progress.
Clinical Evidence When Traditional Wegovy Treatment Plateaus
The STEP trials demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, as reported by Wilding et al., NEJM, 2021. However, these studies also showed that plateaus typically occur between months 6-12, where additional weight loss becomes minimal despite continued treatment. For patients experiencing such plateaus, switching to alternative medications with different mechanisms may help restart progress.
Mounjaro's clinical data from the SURMOUNT trials suggests that the dual GIP/GLP-1 approach can provide benefits for patients who have reached effectiveness limits with single-hormone treatments. Both medications are prescription-only medicines requiring clinical assessment, but the different receptor targets mean that Mounjaro can work effectively even when Wegovy has stopped delivering optimal results for individual patients.
How Wegovy's Mechanism Leads to Effectiveness Plateaus
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural hormone that signals satiety to your brain and slows gastric emptying to maintain fullness. This mechanism effectively reduces appetite and promotes feeling satisfied with smaller meals during initial treatment phases. However, the body's adaptive response can lead to receptor desensitisation or compensatory changes in other hunger pathways over time. Additionally, as weight decreases, metabolic rate adjusts downward, requiring fewer calories for maintenance and making further weight loss progressively more challenging. When these physiological adaptations occur, patients often report that Wegovy stopped working as effectively as during the initial months of treatment.
Seamless Ordering Process for Both Wegovy and Mounjaro
When Wegovy stopped working optimally, transitioning to Mounjaro through EverydayMeds takes just three minutes with our online clinical assessment. The assessment covers your current treatment history, plateau timeline, and medical background to ensure appropriate prescribing. Our qualified prescribers typically review applications within three working days (express 24-hour service available), considering your specific circumstances where previous GLP-1 treatment has reached effectiveness limits. Once approved, both Wegovy and Mounjaro are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transport. This ensures seamless transition between treatments without gaps that could disrupt your weight management progress.
Storage and Practical Considerations During Treatment Switching
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, but their room temperature stability differs significantly when treatment switching occurs. Wegovy maintains effectiveness for up to 6 weeks at room temperature below 30°C, whilst Mounjaro remains stable for 21 days under similar conditions. This difference becomes important during transition periods where you might have overlapping supplies or need travel flexibility. Both use pre-filled pen devices with dose escalation protocols—Wegovy progresses through five doses (0.25mg to 2.4mg) whilst Mounjaro offers six dose levels up to 15mg, providing higher maximum dosing when lower doses have stopped working effectively.
Dual-Action Advantage When Single-Hormone Treatments Plateau
The fundamental difference between Wegovy and Mounjaro lies in their receptor targeting approach, which becomes crucial when Wegovy stopped working due to tolerance or adaptation. Mounjaro's tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, creating complementary pathways for appetite control and metabolic regulation. This dual mechanism can bypass the single-receptor limitations that lead to Wegovy effectiveness plateaus. Research suggests that GIP activation enhances insulin sensitivity and may provide additional metabolic benefits beyond traditional GLP-1-only approaches.
Patients who found that Wegovy stopped delivering results often report renewed progress with Mounjaro's dual-action approach, particularly those who reached plateau phases despite maintaining proper diet and exercise compliance. The combination of GIP and GLP-1 activation can stimulate different appetite control centres and metabolic pathways, potentially overcoming the adaptive responses that limited single-hormone treatment effectiveness. However, both medications require the same commitment to reduced-calorie diet and increased physical activity for optimal results.
Expert Support for Treatment Transition and Ongoing Success
EverydayMeds provides comprehensive support when Wegovy stopped working and you're considering Mounjaro as an alternative treatment option. Our GPhC-registered pharmacy team (#9012878) understands the clinical rationale for switching between different weight management medications and can guide you through the transition process. Use discount codes FIRST40 (new customers) or DOSE25 (returning customers) at checkout to access our competitive pricing on both treatments. We're committed to supporting your long-term weight management journey with expert clinical oversight, reliable medication supply, and the flexibility to adapt your treatment when circumstances change. Both Wegovy and Mounjaro are available through our streamlined service—your prescriber can help you choose the most appropriate option for your current needs.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
